Next Article in Journal
Vascular Repair by Grafting Based on Magnetic Nanoparticles
Next Article in Special Issue
Impact of Sex on Proper Use of Inhaler Devices in Asthma and COPD: A Systematic Review and Meta-Analysis
Previous Article in Journal
The Use of Polymer Blends in the Treatment of Ocular Diseases
Previous Article in Special Issue
Experimental Evaluation of Dry Powder Inhalers during Inhalation and Exhalation Using a Model of the Human Respiratory System (xPULM™)
 
 
Article
Peer-Review Record

Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder

Pharmaceutics 2022, 14(7), 1432; https://doi.org/10.3390/pharmaceutics14071432
by Tushar Saha 1, Shubhra Sinha 2, Rhodri Harfoot 2, Miguel E. Quiñones-Mateu 2,3 and Shyamal C. Das 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Pharmaceutics 2022, 14(7), 1432; https://doi.org/10.3390/pharmaceutics14071432
Submission received: 27 May 2022 / Revised: 29 June 2022 / Accepted: 1 July 2022 / Published: 8 July 2022
(This article belongs to the Special Issue Dry Powders for Inhalation: Formulation Design and Quality Assessment)

Round 1

Reviewer 1 Report

Firstly, thank you to the editor and authors to give me this chance to re-review this interesting work. The manuscript after revision and adding the part of in vitro work is persuasive and its application has more chances.  

Author Response

Please find the attached file.

Author Response File: Author Response.docx

Reviewer 2 Report

Attached PDF

Comments for author File: Comments.pdf

Author Response

Please find the attached file.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

Line 29: The word ‘original’ must be replaced with ‘ivermectin solution’ if the cell toxicity assay in section 2.12 was performed with an ivermectin solution. 

Moreover in the same section, Line 287 the sentence  ‘empirically determined serial dilutions of the corresponding compounds’ should be replaced with  a detailed description of the solutions prepared for ivermectin, ivermectin dry powder and L-leucine alone (starting concentrations, solvent or mixture of solvents) and the dilutions made with the cell medium to treat the cells.

A Schematic Figure of the dissolution-permeation apparatus must be included to enhable the reader to follow the description in section 2.11.

An explanation of the values above 100% ‘in Table 3 must be reported in the text. 

Figure 5: Have the axes been drawn on the same figure? Please check.

 

Author Response

A point by point response is attached. 

Author Response File: Author Response.docx

Back to TopTop